Kornimate/medical-research-clean huggingface dataset:
applying shear wave elastography for adjunct steroid on tuberculous lymphadenitis

Conditions: Tuberculous Lymphadenitis

Summary: 1. to prospectively collect the radiologic data from the initial phase till the post-treatment phase of tuberculous lymphadenitis. 2. to prospectively investigate the benefits of corticosteroid on reduction of paradoxical upgrading reaction in patients with tuberculous lymphadenitis based on the results of shear wave elastography. 3. to investigate the potential biomarker of host immunity in response to tuberculosis and predict the development of paradoxical upgrading reaction.

tuberculosis remained one of the top ten leading cause of death worldwide. there were more than 10 million new diagnoses per year, and up to 1.2 million deaths caused by tuberculosis. extra-pulmonary tuberculosis is defined as infection outside the lung. tuberculous lymphadenitis is the most common site of extra-pulmonary tuberculosis, constituting around 30-50% of all cases. a unique manifestation with worsening of symptoms, called paradoxical upgrading reaction (pur), may develop in 20-50% of patients with tuberculous lymphadenitis during the therapy. common presentations of the pur include swollen lymphadenitis with pain or rupture with pus. patients may fail to complete the treatment and jeopardize the development of drug-resistant pathogen. limited studies investigated the risk factors associated with the pur. in our prior study, ultrasound shear wave elastography offers quantified values as the objective parameters to successfully predict the occurrence of pur. in this study, we aim to investigate the effect of corticosteroid as an adjunct therapy to reduce the pur from happening in patients with tuberculous lymphadenitis.

Eligibility criteria:
inclusion criteria: * participants diagnosed of tuberculous lymphadenitis. * the diagnosis of tuberculous lymphadenitis must qualify any of the following criteria: 1. microbiological evidence (culture or nucleic acid amplification test) 2. histology specimen featuring caseating granulomatous inflammation with acid-fast bacilli on smear, or clinical response to anti-tuberculosis therapy. exclusion criteria: * participants with age \< 18 years * diagnoses based on histologic report turned out to be non-tuberculosis mycobacterial infection * the tuberculous lymphadenitis involved was surgically removed, without available target to be monitored * participant under systemic (oral or parenteral) steroid therapy. * participant with active hepatitis b virus infection * participant reluctant to be enrolled in the trial

Keywords: tuberculous lymphadenitis, paradoxical upgrading reaction
evaluation of conventional non-invasive mechanical ventilation (niv) versus an automatic ventilation mode.

Conditions: Hypoxemic Respiratory Failure; Hypercapnic Respiratory Failure

Summary: to evaluate the polysomnographic performance of an automatic ventilatory mode compared with the gold standard (manual polysomnographic titration) to adjust chronic non-invasive ventilation by means of a randomized cross-over study.

prospective randomized crossover study in 26 patients with chronic non-invasive ventilation (niv) criteria, comparing the niv titration with polysomnography vs an automatic mode of ventilation. it will be compared with clinical parameters of ventilation, blood analysis and inflammation reactants as well as evaluating the patient's comfort after each mode.

Eligibility criteria:
inclusion criteria: chronic respiratory failure * diurnal hipercapnia and/or nocturnal hypoventilation (ct90% \>10%) exclusion criteria: * under 18 years old. * presence of severe uncontrolled cardiac comorbidity. * impossibility to achieve adaptation to therapy in the training session.

Keywords: niv hypoxemia hypercapnia
motor disability of children with cerebral palsy using motor transcranial magnetic stimulation

Conditions: Cerebral Palsy

Summary: transcranial magnetic stimulation (tms) has opened new potential avenues for the treatment of neuropsychiatric diseases via the effects of modulation on neuroplasticity. repetitive tms (rtms) is a non-invasive method of stimulation neural pathways in the brain of conscious subjects through the intact scalp. the investigators hypothesize that excitatory rtms applied over the motor cortex would increase motor cortex activity and result in an increase in the inhibitory input through the corticospinal tract to the spinal cord, thus reducing alpha neuron hyperactivity and consequently clinical spasticity. in this study, the investigators will apply the stimulation on the legs motor cortex area, which can cover supplemental motor area (sma). therefore, not only the spasticity, but also the motor control of legs both can be modulated by stimulation. theta burst stimulation is a condition of rtms which was designed by the co-investigator. it has controllable, consistent, long-lasting, and powerful effects on motor cortex physiology and behavior. the investigators therefore design this protocol using theta burst stimulation on the motor cortex of the patients of cerebral palsy. the investigators expect that there would be an effect on the reduction of spasticity after rtms on the brain of children with cp, thus improving the motor control of legs.

in this study, the investigators design 3 steps to find out the optimal condition of rtms for the treatment and managing of motor disability of cp. the first is to find out the optimal intensity of rtms. the second is to find out the optimal duration of rtms and long term effects. the third is to compare the effectiveness of botulinum toxin injection, rtms, and combined therapy (botulinum toxin injection and rtms) for children with cp.

Eligibility criteria:
inclusion criteria: * diagnosis of mild to moderate cp with spastic diplegia or hemiplegia according to clinical criteria * age 7-20 years * no use of botulinum toxin in the past 4 months * no significant perceptual or communication disturbances * no other peripheral or central nervous system dysfunction * no active inflammatory or pathologic changes in lower limb joints during the previous 6 months * no active medical problems, such as pneumonia, upper gastrointestinal bleeding, or urinary tract infection * no active problems of epilepsy and eeg without epileptiform discharge * ability to walk 20m without walking aids, such as a cane, quadricane or walker exclusion criteria: * metabolic disorders, such as inborn error of metabolism, electrolyte, and endocrine disorders. * active infectious disease, such as meningitis and encephalitis. * patients with active medical problems, such as pneumonia, upper gastrointestinal bleeding, or urinary tract infection. * poor compliance or intolerance for the tms therapy * subjects with metallic implants or pregnancy. * eeg show epileptiform discharge

Keywords: cerebral palsy transcranial magnetic stimulation
resistant starch on glycemic response in older adults

Conditions: Hyperglycemia

Summary: the purpose of this study was to determine how blood glucose changes after eating energy bars containing resistant starch type 4 compared with bars made with puffed wheat in healthy older adults.

to measure the blood glucose response, we collected blood samples before eating and 15, 30, 45, 60, 90 and 120 minutes after eating each bar. the incremental area under the curve was used to calculate glycemic index.

Eligibility criteria:
inclusion criteria: * apparently healthy (not diagnosed with disease) * over 60 years of age exclusion criteria: * diagnosed with diabetes or other metabolic disorder * allergies to wheat * non-smokers

Keywords: aging diabetes diet fiber
biomechanical effects of duloxetine on bladder and sphincter muscle function in women in pure genuine stress incontinence

Conditions: Urinary Stress Incontinence

Summary: double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence


Eligibility criteria:
inclusion criteria: * female * between 18 and 75 years of age * diagnosis of gsi * have discrete episodes of incontinence exclusion criteria: * positive urine culture at visit 1 * use of maoi * have had continence or urethral surgery * use of anti-incontinence device, vaginal pessaries or medications for the treatment of urinary incontinence * began pelvic floor muscle exercises within 6 months prior to study entry.
nupro(r) sensodyne prophylaxis paste with novamin(r)sensitivity relief study

Conditions: Tooth Hypersensitivity

Summary: the study is intended to verify through clinical measurement that the nupro sensodyne prophylaxis paste with novamin provides immediate sensitivity relief as well as extended relief up to 28 days.

it is hypothesized that the prophy paste with novamin(r)will give patients immediate sensitivity relief, as well as sensitivity relief up to 4 weeks (28 days) after measurement.

Eligibility criteria:
inclusion criteria: * availability to complete in the 28 day duration of the study. * two sensitive teeth which are not adjacent to each other and preferably in different quadrants and demonstrate cervical erosion, abrasion, and gingival recession. * qualifying response to tactile stimuli as defined by a score of \</= 20 grams. * qualifying response to air blast stimuli as defined by a score of \>/= 1 on the schiff cold air sensitivity scale. * good general health with no known allergies to products being tested. * use of a non-desensitizing dentifrice for 3 weeks prior to entry into the study. * able to follow study procedures and instructions. * must have a minimum of 10 natural evaluable teeth, excluding 3rd molars. exclusion criteria: * individuals who exhibit gross oral pathology * females who may be pregnant or lactating or intending to become pregnant * individuals who require anesthetic during scaling * dental pathology which may cause pain similar to tooth sensitivity * individuals with large amounts of calculus * subjects with active infectious diseases such as hepatitis, hiv or tuberculosis * any condition requiring antibiotic prophylaxis for dental treatment * excessive gingival inflammation * individuals who had their teeth cleaned within 30 days of the screening appointment * individuals who have had a desensitizing treatment or tooth bleaching within 90 days of screening appointment. * oral pathology, chronic disease, or history of allergy to test products * advanced periodontal disease or treatment for periodontal disease (including surgery) within the past twelve months. * sensitive teeth with mobility greater than one. * teeth with extensive/defective restorations (including prosthetic crowns), suspected pulpitis, caries, cracked enamel, or used as abutments for removable partial dentures. * regular use of sedatives, anti-inflammatory drugs, or analgesic * participation in a desensitizing dentifrice study or regular use of a desensitizing dentifrice within the past 4 weeks. * current participation in any other clinical study or receipt of an investigational drug within 30 days of the screening visit at the start of the study. * personnel; a) an employee of the sponsor; b) a member or relative of the study site staff directly involved with the study. * allergies to oral care products, personal care consumer products, or their ingredients. * any subject who, in the judgment of the investigator, should not participate in the study.
colonic resection for cancer as diabetogenic risk factor

Conditions: Glucose Metabolism Disorders; Colon Cancer; Surgery; Chemotherapy Effect

Summary: colon cancer (cc) survivors have an increased risk of developing t2d. a recent study revealed that the surgical procedures per se may be causally involved. hence, left-sided colon resections increased the risk of developing t2d. in addition, treatment with chemotherapy may play a role in the pathogenesis. given the steadily improving survival rate after a cc diagnosis, prevention of secondary diseases such as t2d is important to improve quality of life in these patients and to reduce socioeconomic expenses. this study aims to elucidate the effect of resection of tumors located in the left part of the colon on pathophysiological intermediates, which may lead to t2d 12 months post-surgery or later. the physiological mechanism might be a changed postprandial secretion of gut hormones including glucagon-like peptide-1 (glp-1) secreted from l-cells in the left part of the colon. the investigators will evaluate changes in primarily glucose homeostasis as well as in gastrointestinal hormones, microbiota, visceral fat accumulation and markers of low-grade inflammation etc. in cc survivors who underwent a left hemicolectomy or sigmoidectomy. material and methods: 60 patients will be included in this explorative clinical study. patients will be divided into 4 groups depending on surgical procedure and treatment with chemotherapy. in the group of patients undergoing left hemicolectomy or sigmoidectomy ± treatment with chemotherapy 2 x 15 patients will be included, and in the group of patients scheduled to undergo right hemicolectomy ± treatment with chemotherapy another 2 x 15 patients will be included. during the 3 study visits (before surgery, 3-4 weeks post-surgery and 12 months post-surgery) the following tests will be performed: an oral glucose tolerance test, blood and fecal sampling, a dxa scan and an ad libitum meal test. implications: with this study the investigators expect to obtain an insight in the pathogenesis behind the possible development of t2d in cc survivors who underwent a resection of the left part of the colon ± treatment with chemotherapy. this insight may also help scientists develop new ways of treating or preventing t2d in general.


Eligibility criteria:
inclusion criteria: inclusion criteria: * adult (\> 18 yrs.) * asa score 1-3 * signed written informed consent * hba1c \<48 mmol/mol * hemoglobin ≥ 6,5 mmol/l exclusion criteria: * • pregnancy * known type 1 or 2 diabetes * inflammatory bowel disease (ulcerous colitis and crohns' disease). * prior major abdominal surgery including bariatric surgery or colorectal resections * treatment with agents that may interfere with glucose homeostasis and or appetite or reduce the chance of successful follow-up examination * planned stoma
incidence of hyperpigmentation in black patients with multiple myeloma treated with immunomodulatory drugs

Conditions: Multiple Myeloma

Summary: the purpose of this study is to measure the incidence of hyperpigmentation in black participants with multiple myeloma (mm) treated with immunomodulatory drugs (imids) compared with black participants with mm not treated with imids. the study will use de-identified data from electronic medical records in the flatiron health database.


Eligibility criteria:
inclusion criteria: * participants ≥18 years of age at index date * participants with new diagnosis of mm as defined by: * icd-9-cm: 203.0x and/or icd-10-cm: c90.0x or c90 during the study period * at least two documented clinical visits for mm on different days and occurring on or after january 1, 2011 * participants who received at least one systemic mm therapy on or after initial mm diagnosis * participants who did not receive clinical study drug at any time during the observation period * participants with race information exclusion criteria: * exclusion criteria * patients with less than 6 months of medical data during the prior or follow-up period * patients in more than one race category (mix race), missing race, unknown race, and "other" race * patients diagnosed with the following hematological cancers on or prior to the index date: * myelodysplastic syndromes (icd-9: 238.74, 238.75; icd-10: d46.xx) * mantle cell lymphoma (icd-9: 200.4x, icd-10: c83.1x) * follicular lymphoma (icd-9: 202.0x, icd-10: c82.xx) * marginal zone lymphoma (icd-9: 200.3x, icd-10: c83.4x) * patients with evidence of skin hyperpigmentation (icd-9: 709.00, 709.09; icd-10: l81.0, l81.1, l81.4, l81.8) on or prior to the index date * 709.00 dyschromia, unspecified * 709.09 other dyschromia * l81.0 post inflammatory hyperpigmentation * l81.1 chloasma/melasma * l81.4 other melanin hyperpigmentation * l81.8 other specified disorders of pigmentation
mobile weight-support therapy (mwest) for mobility after geriatric fracture

Conditions: Distal Femur Fracture

Summary: this is a two-year study proposal to assess feasibility of mwest (mobile weight-support therapy) implementation after geriatric fracture and its effects on functional and patient-reported outcomes. the goal of this study is to improve mobilization of geriatric lower extremity trauma patients, with the aim of improving overall functional and patient-reported outcomes while decreasing complications and readmissions. almost 50% of the adult population in the united states has osteopenia or osteoporosis, with over 2 million fragility fractures per year and a projected $25 billion in costs by 2025. these patients are at high risk for readmission due to complications, and at increased risk of mortality with these complications. sarcopenia, a generalized loss of skeletal muscle associated with aging, has also been associated with increased disability and increased risk of future fracture in these patients. the investigator's study aims to assess the value of weight-support therapy for geriatric patients with lower extremity trauma in improving their overall risk of future injury and disability.

the goal of this study is to improve mobilization of geriatric lower extremity trauma patients, with the aim of improving overall functional and patient-reported outcomes while decreasing complications and readmissions. almost 50% of the adult population in the united states has osteopenia or osteoporosis, with over 2 million fragility fractures per year and a projected $25 billion in costs by 2025. these patients are at high risk for readmission due to complications, and at increased risk of mortality with these complications. sarcopenia, a generalized loss of skeletal muscle associated with aging, has also been associated with increased disability and increased risk of future fracture in these patients. the investigator's study aims to assess the value of weight-support therapy for geriatric patients with lower extremity trauma in improving their overall risk of future injury and disability.

Eligibility criteria:
inclusion criteria: * 55 and older * distal femur fracture * able to walk prior to fracture exclusion criteria: * patients unable to walk without any assistive devices post-injury * patients too medically unstable to participate in physical therapy
changes in out-patient visits in taiwan during the time of global covid-19 pandemic

Conditions: Patient Preference

Summary: the covid-19 pandemic becomes a global challenge. this study aims to analyze the possible changes in out-patient visits during the time of covid-19 pandemic between january and june, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

using the statistical data of the health insurance bureau, this study aims to analyze the possible changes in out-patient visits during the time of covid-19 pandemic between january and june, 2020, compared with the same period in 2019, and the impact of the related healthy policies.

Eligibility criteria:
inclusion criteria: * patients visited the out-patient clinic using the health insurance cards. exclusion criteria: * patients visited the out-patient clinic without using the health insurance cards.
study to assess gw642444 in asthma patients

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this is a study of gw642444m, a long-acting beta 2 specific agonist. this study will examine gw642444m via the inhaled route and will assess the efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of gw642444m in persistent asthmatics. this study will be a single-centre, placebo-controlled, dose-ascending, five-way crossover in 30 asthmatic patients. key assessments: efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics will be assessed by measurement of fev1, blood pressure, pulse rate, 12-lead ecgs, clinical laboratory safety tests, collection of adverse events and blood samples.


Eligibility criteria:
inclusion criteria: * subjects with a documented history of persistent asthma, with the exclusion of other significant pulmonary diseases * female subjects of non-child bearing potential (i.e. post-menopausal or surgically sterile) * subjects who are current non-smokers, who have not used any inhaled tobacco products (snuff is permitted) in the 12 month period preceding the screening visit and who have a pack history of less than 10 pack years. * subjects with clinically stable persistent asthma within the 4 weeks preceding the screening visit and with a screening pre-bronchodilator fev1 between 60 and 90% predicted (having abstained from bronchodilators for the required period). predicted values are based on the eccs 1993 normal ranges * during the screening visit, subjects must demonstrate the presence of reversible airway disease, defined as an increase in fev1 of greater than 12.0% over baseline and an absolute change of greater than 300 ml within 30 minutes following a single 400 mcg salbutamol dose. * subjects who are currently taking ics at a total daily dose of 200 to 500 mcg of fp or equivalent ics exclusion criteria: * subjects who have a past or present disease, which as judged by the investigator and the medical monitor, which may affect the safety of the subject or outcome of this study * a screening holter ecg tracing that reveals clinically concerning arrhythmias (including, but not limited to, ventricular ectopic runs of 4 beats, r on t phenomena, bigeminy, trigeminy). * a mean qtc(b) value at screening \>430 msec (male) / \>450 msec (female) or an ecg that is not suitable for qt measurements (e.g. poorly defined termination of the t wave). * any adverse reaction including immediate or delayed hypersensitivity to any ß2 agonist or sympathomimetic drug, or known or suspected sensitivity to the constituents of gw642444 inhalation powder (e.g., lactose or coa). * subjects weighing \< 50 kg * subjects who have participated in any gsk study involving administration of coa.

Keywords: safety gw642444m single dose pharmacodynamics pharmacokinetics gw642444h tolerability
prediction of claustrophobia during mr imaging

Conditions: Claustrophobia

Summary: the objective of the study is to search for possible predictors for claustrophobia during magnetic resonance (mr) imaging. a claustrophobic event shall be defined by an incomplete examination, or a complete examination that requires coping actions by the staff. coping actions may consist of the administration of sedatives, prism glasses, an mr imaging test run with the patient, a pause, the prone position, an escort in the scanner room, and supportive communication. the investigators hypothesize that there is a difference between patients with and without events in their scores on the claustrophobia questionnaire and several further psychometric questions. other factors may also favour events like patient characteristics, examined region, duration of the examination and scanner type. therefore, predictors could identify patients who are likely to experience claustrophobia during mr imaging so that they can receive the appropriate support by the staff to complete their examination. thus a larger patient population could benefit from mr imaging.


Eligibility criteria:
inclusion criteria: * inpatients and outpatients referred to mr imaging with a clinical indication of any part of the body * mentally and physically able to fill out a questionnaire * sufficient german language skills exclusion criteria: * age under 18 years * patients from the intensive care unit * severe emergencies * surgery during mr imaging * participation in other studies * fetal and prenatal examinations * referral from medical jurisprudence

Keywords: claustrophobia magnetic resonance imaging mri anxiety anxious patients phobic disorders anxiety disorders mental disorders